Interferon-induced enhancement of 2',5'-oligoadenylate synthetase in mid-gut carcinoid tumours

Grandér, Dan; Einhorn, Stefan; Öberg, Kjell; Lundqvist, M-L.; Jansson, E; Eriksson, Barbro

doi:10.1016/0140-6736(90)91879-f

Cited by 60 publications

(25 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is also important to use the predictive test for different therapies (2-5-A-synthetase and OctreoScan) (9,12) that are available for an optimal management of these patients.…”

Section: Eriksson and K Obergmentioning

confidence: 99%

An Update of the Medical Treatment of Malignant Endocrine Pancreatic Tumors

1993

View full text Add to dashboard Cite

“…It is also important to use the predictive test for different therapies (2-5-A-synthetase and OctreoScan) (9,12) that are available for an optimal management of these patients.…”

Section: Eriksson and K Obergmentioning

confidence: 99%

An Update of the Medical Treatment of Malignant Endocrine Pancreatic Tumors

1993

View full text Add to dashboard Cite

“…Biotherapy a-interferon was initially discovered in 1957 [45] and it has later been shown to induce cell blocking in G0 and G1, reduce mRNA for hormones and growth factors and to generally stimulate the immune system [46,47]. In 1983, Ö berg et al published data showing that a-interferon could control hormone secretion, clinical symptoms and tumor growth in carcinoid tumors [48].…”

Section: Chemotherapymentioning

confidence: 99%

Treatment of endocrine pancreatic tumors

Fjällskog

Janson

2005

Acta Oncologica

View full text Add to dashboard Cite

“…On the other hand, immunological properties such as the induction of natural killer activity and the enhancement of the expression of antigens on the tumour might play a role. The mechanism of action as elucidated in hairy cell leukaemia (Vedantham et al, 1992), the carcinoid (Grander et al, 1990) and the observation that the addition of 20 mg of prednisone had no impact on the anti-tumour effect (Fossa et al, 1990) Aulitzky et al (1989), so far unconfirmed. applying an individually tailored dose of IFN-y based on parameters of immune stimulation such as neopterin excretion.…”

Section: Toxicitymentioning

confidence: 99%

“…The mechanisms of action of IFN-x are very pleiotropic, and many mechanisms can be responsible for the observed anti-tumour effect. There are actions directly on the tumour such as an antiproliferative effect, and there are indications that the induction of 2',5'-oligoadenylate synthetase is related with this potential (Grander et al, 1990). On the other hand, immunological properties such as the induction of natural killer activity and the enhancement of the expression of antigens on the tumour might play a role.…”

Section: Toxicitymentioning

confidence: 99%

EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma

Mulder

Oosterhof²,

Bouffioux³

et al. 1995

Br J Cancer

View full text Add to dashboard Cite

In the treatment of renal cell carcinoma both complete (CRs) and partial remissions (PRs) have been obtained using recombinant (r) interferon alpha (IFN-alpha), with response rates ranging from 0 to 31% (mean 16%). rIFN-gamma is a potent immunostimulating agent, but the clinical experience of its use is limited and results are conflicting. In a phase II study with the combination of rIFN-alpha 2c (Boehringer Ingelheim) and rIFN-gamma (Genentech, supplied by Boehringer Ingelheim) in 31 eligible patients, a response rate of 25% was recorded. Based on this observation a randomised phase III study was initiated to investigate the possible advantage of the addition rIFN-gamma to rIFN-alpha 2c treatment. Treatment consisted of rIFN-alpha 2c 30 micrograms m-2 = 10 x 10(6) IU m-2 s.c. twice weekly in arm A and the same dose of rIFN-alpha combined with rIFN-gamma 100 micrograms m-2 = 2 x 10(6) IU m-2 in arm B. Eligibility criteria included documented progression of disease; patients with bone lesions only and overt central nervous system metastases were excluded. Between November 1988 and September 1990, 102 patients were entered into the study. An interim analysis showed a response in 7/53 (13%) patients (two CRs and five PRs) in the rIFN-alpha 2c monotherapy arm and in 2/45 (4%) (one CR and one PR) patients in the combination arm. This difference was not statistically significant (P = 0.17). The probability of missing an eventual 10% advantage for the combination is 0.001. The numbers are insufficient to rule out a negative effect of the addition of rIFN-gamma. The dose intensity of IFN-alpha 2c for the two treatment arms was the same. The addition of rIFN-gamma does not improve the response rate of rIFN-alpha 2c monotherapy. A possible detrimental effect cannot be excluded.

show abstract

Interferon-induced enhancement of 2',5'-oligoadenylate synthetase in mid-gut carcinoid tumours

Cited by 60 publications

References 16 publications

An Update of the Medical Treatment of Malignant Endocrine Pancreatic Tumors

An Update of the Medical Treatment of Malignant Endocrine Pancreatic Tumors

Treatment of endocrine pancreatic tumors

EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma

Contact Info

Product

Resources

About